Showing 2791-2800 of 5909 results for "".
- American Medical Association’s New President a ‘Passionate Defender of the Independent Physician’https://modernod.com/news/american-medical-associations-new-president-a-passionate-defender-of-the-independent-physician/2477875/Susan Bailey, MD, the new president of the American Medical Association (AMA), called for physicians to advocate at the highest levels of government and insurance companies for support needed “to sustain private practice during a pandemic that threatens its very survival,” according t
- AbbVie Enters Deal to Develop Antibody Therapeutic for COVID-19https://modernod.com/news/abbvie-enters-deal-to-develop-antibody-therapeutic-for-covid-19/2477869/AbbVie entered into a collaboration with Harbour BioMed, Utrecht University, and Erasmus Medical Center to develop an antibody therapeutic to prevent and treat COVID-19, the parties announced Friday. The fully human, neutralising antibody 47D11, which targets the conserved domain of the spike pro
- Diabetic Retinopathy Appears Linked to Depressionhttps://modernod.com/news/diabetic-retinopathy-appears-linked-to-depression/2477864/People with diabetic retinopathy experience depression at higher rates than the general population, but the rate decreases at the most severe stage of the disease, an analysis of a large database shows, according to a Medscape report.
- AstraZeneca Targeting Over 2 Billion COVID-19 Vaccine Doses After Latest Dealshttps://modernod.com/news/astrazeneca-targeting-over-2-billion-covid-19-vaccine-doses-after-latest-deals/2477865/AstraZeneca said it signed agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance and the Serum Institute of India (SII) in a move aimed at broadening global access to an experimental COVID-19 vaccine being developed at the University of Oxford. The
- BVI Launches CryoTreq for Treatment of Retinal Tears and Detachmentshttps://modernod.com/news/bvi-launches-cryotreq-for-treatment-of-retinal-tears-and-detachments/2477863/BVI announced the European launch of CryoTreq—a single-use, handheld cryosurgery device for ophthalmology. The device functions without external connections to equipment, gas tanks, or power and does not require any service or maintenance. CryoTreq enables a minimally invasive ab externo a
- Devlyn Optical Partnering with Eyenuk to Offer Diabetic Retinopathy Screeninghttps://modernod.com/news/devlyn-optical-partnering-with-eyenuk-to-offer-diabetic-retinopathy-screening/2477858/Eyenuk and Devlyn Optical, an optical retailer with over 1,000 stores in Mexico, Guatemala, El Salvador, and the US, announced that they will collaborate to pilot diabetic retinopathy (DR) screening services at Devlyn
- AAO Statement on Death of George Floyd and Its Aftermathhttps://modernod.com/news/aao-statement-on-death-of-george-floyd-and-its-aftermath/2477850/The American Academy of Ophthalmology (AAO) released a statement on Monday regarding the death of George Floyd and its aftermath. The statement reads: “The American Academy of Ophthalmology deplores the senseless death of George Floyd and others under similar circumstances. We
- Expert: Hospitals Should Prepare For Pent-Up Demand From Non-COVID-19 Patientshttps://modernod.com/news/expert-hospitals-should-prepare-for-pent-up-demand-from-non-covid-19-patients/2477848/While much of the focus has been on “flattening the curve” when it comes to COVID-19, experts warn hospitals should be prepared for another potential surge: pent-up demand for deferred care, according to a FierceHealthcare
- Port Delivery System With Ranibizumab Shows Positive Phase 3 Results in Wet AMDhttps://modernod.com/news/port-delivery-system-with-ranibizumab-shows-positive-phase-3-results-in-wet-amd/2477824/Genentech announced positive topline results from the phase 3 Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with wet age-related macular degeneration (AMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continu
- TearClear Appoints Dr. Amir Shojaei Chief Development Officerhttps://modernod.com/news/tearclear-appoints-dr-amir-shojaei-chief-development-officer/2477803/TearClear Corp. announced the appointment of Amir Shojaei, PharmD, PhD, as Chief Development Officer. Over his 23-year career, Dr. Shojaei has focus